Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Common Equity (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Common Equity for 12 consecutive years, with $639.1 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 27.4% to $639.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $639.1 million through Dec 2025, down 27.4% year-over-year, with the annual reading at $639.1 million for FY2025, 27.4% down from the prior year.
  • Common Equity hit $639.1 million in Q4 2025 for Viking Therapeutics, down from $713.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $933.9 million in Q1 2024 to a low of $134.1 million in Q1 2023.
  • Historically, Common Equity has averaged $470.0 million across 5 years, with a median of $358.3 million in 2023.
  • Biggest five-year swings in Common Equity: fell 29.01% in 2022 and later skyrocketed 596.6% in 2024.
  • Year by year, Common Equity stood at $201.9 million in 2021, then dropped by 28.02% to $145.3 million in 2022, then skyrocketed by 139.76% to $348.4 million in 2023, then skyrocketed by 152.65% to $880.3 million in 2024, then dropped by 27.4% to $639.1 million in 2025.
  • Business Quant data shows Common Equity for VKTX at $639.1 million in Q4 2025, $713.0 million in Q3 2025, and $795.5 million in Q2 2025.